TY - JOUR
T1 - Association of home and ambulatory blood pressure changes with changes in cardiovascular biomarkers during antihypertensive treatment
AU - Yano, Yuichirou
AU - Hoshide, Satoshi
AU - Shimizu, Motohiro
AU - Eguchi, Kazuo
AU - Ishikawa, Joji
AU - Ishikawa, Shizukiyo
AU - Shimada, Kazuyuki
AU - Kario, Kazuomi
N1 - Funding Information:
Supplementary material is linked to the online version of the paper at http:// www.nature.com/ajh acknowledgements:This study was financially supported in part by a grant from the Japan heart Foundation, Tokyo.
PY - 2012/3
Y1 - 2012/3
N2 - Background Our aim was to assess whether home blood pressure (HBP) and ambulatory BP monitoring measurement (ABPM), in addition to office BP (OBP) predict changes of cardiovascular biomarkers during antihypertensive treatment. Methods Two hundred and fifty-two hypertensive patients (mean age, 68 years; men: 41%) underwent measurements of OBP, HBP, ABPM, and cardiovascular biomarkers (urinary albumin excretion (UAE) and brain natriuretic peptide (BNP)) before and after 6 months of treatment with candesartan (± thiazide-diuretics). Results During the intervention, the OBP, HBP, daytime and night-time BP, and UAE levels were all significantly reduced (all P< 0.01). BNP was reduced only in the patients using diuretics (P = 0.003). For predicting the treatment-induced change in UAE, each of home systolic BP (SBP) and night-time SBP changes, but not daytime SBP change, had independent and significant value beyond OBP measurement (both P< 0.05). In contrast, for predicting the treatment-induced change in BNP, night-time SBP changes, but not home or daytime SBP changes, had significant value beyond OBP measurement (both P< 0.05). Patients who achieved a reduction in all three SBP parameters (office, home, and night-time SBP; n = 122) showed a more significant reduction of UAE compared with those who did not (52.6 vs. 32.5%; P = 0.001), and patients who achieved a reduction in both office and night-time SBP (n = 134) showed a more significant reductions of BNP than those who did not (12.9 vs. 12.8%; P< 0.05). Conclusions HBP and ABPM measurements, particularly night-time SBP values provide additional information for predicting treatment-induced changes of cardiovascular biomarkers when used in conjunction with office SBP measurement during antihypertensive treatment.
AB - Background Our aim was to assess whether home blood pressure (HBP) and ambulatory BP monitoring measurement (ABPM), in addition to office BP (OBP) predict changes of cardiovascular biomarkers during antihypertensive treatment. Methods Two hundred and fifty-two hypertensive patients (mean age, 68 years; men: 41%) underwent measurements of OBP, HBP, ABPM, and cardiovascular biomarkers (urinary albumin excretion (UAE) and brain natriuretic peptide (BNP)) before and after 6 months of treatment with candesartan (± thiazide-diuretics). Results During the intervention, the OBP, HBP, daytime and night-time BP, and UAE levels were all significantly reduced (all P< 0.01). BNP was reduced only in the patients using diuretics (P = 0.003). For predicting the treatment-induced change in UAE, each of home systolic BP (SBP) and night-time SBP changes, but not daytime SBP change, had independent and significant value beyond OBP measurement (both P< 0.05). In contrast, for predicting the treatment-induced change in BNP, night-time SBP changes, but not home or daytime SBP changes, had significant value beyond OBP measurement (both P< 0.05). Patients who achieved a reduction in all three SBP parameters (office, home, and night-time SBP; n = 122) showed a more significant reduction of UAE compared with those who did not (52.6 vs. 32.5%; P = 0.001), and patients who achieved a reduction in both office and night-time SBP (n = 134) showed a more significant reductions of BNP than those who did not (12.9 vs. 12.8%; P< 0.05). Conclusions HBP and ABPM measurements, particularly night-time SBP values provide additional information for predicting treatment-induced changes of cardiovascular biomarkers when used in conjunction with office SBP measurement during antihypertensive treatment.
UR - http://www.scopus.com/inward/record.url?scp=84857065363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857065363&partnerID=8YFLogxK
U2 - 10.1038/ajh.2011.229
DO - 10.1038/ajh.2011.229
M3 - Article
C2 - 22170010
AN - SCOPUS:84857065363
VL - 25
SP - 306
EP - 312
JO - American Journal of Hypertension
JF - American Journal of Hypertension
SN - 0895-7061
IS - 3
ER -